Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar;41(3):611-616.
doi: 10.1007/s00296-020-04783-2. Epub 2021 Jan 23.

Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study

Diane Marsman  1 , Thomas Bolhuis  2 , Nathan den Broeder  2 , Frank van den Hoogen  2   3 , Alfons den Broeder  2   3 , Aatke van der Maas  2
Affiliations
Observational Study

Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study

Diane Marsman et al. Rheumatol Int. 2021 Mar.

Abstract

Guidelines on management of polymyalgia rheumatica (PMR) recommend early introduction of methotrexate (MTX), especially in patients with worse prognosis, although evidence on clinical efficacy of MTX in PMR is limited. Our objective was to assess MTX efficacy in real-world PMR care. Retrospective data of newly diagnosed PMR patients who started MTX were compared to control patients in whom MTX was not started at the first flare. Main outcomes were number of flares per year (Poisson regression) and weighted daily glucocorticoid (GC)-dose (linear regression), and flare incidence rate ratio in the MTX group only. 240 patients were selected; 39 patients in the MTX group and 201 in the control group. The yearly incidence rate ratio of flares in the MTX versus control group was 0.80 (95% CI 0.45-1.42). The yearly flare rate was 1.22 before and 0.43 after MTX initiation, resulting in an incidence ratio of 0.35 (95% CI 0.23-0.52). Adjusted time weighted daily GC dose was higher in the MTX versus control group (ratio 1.37, 95% CI 1.04-1.80). No clear effect of MTX on flares was found and time weighted daily GC dose was higher, possibly due to residual confounding by indication. However, the clearly reduced flare rate after MTX start might be suggestive for a beneficial effect of MTX.

Keywords: Flare; Glucocorticoid sparing; Methotrexate; Polymyalgia rheumatica.

PubMed Disclaimer

Comment in

References

    1. Buttgereit F, Dejaco C, Matteson EL et al (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315:2442–2458 - DOI
    1. González-Gay MA, Matteson EL, Castañeda S (2017) Polymyalgia rheumatica. Lancet 390(10103):1700 - DOI
    1. Caporali R, Cimmino MA, Montecucco C et al (2011) Glucocorticoid treatment of polymyalgia rheumatica. ClinExpRheumatol 29(5 Suppl 68):S143–S147
    1. Dejaco C, Singh YP, Perel P, European League Against Rheumatism, American College of Rheumatology (2015) Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799–1807 - DOI
    1. van der Veen MJ, Dinant HJ, van Booma C et al (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55:218–223 - DOI

Publication types

LinkOut - more resources